Share on Facebook Share on Twitter Email
Answers.com

Framingham Heart Study

 
 

The Framingham Heart Study is a longitudinal study of a defined population in Massachusetts, initiated in 1948. The Framingham Study was conceived by Joseph Mountin, Assistant Surgeon General and head of the Division of Chronic Diseases of the U.S. Public Health Service. Mountin saw that cardiovascular diseases were replacing infectious diseases as the major cause of mortality in the United States. He responded to the suggestion of David Rutstein of Harvard University that the study be set up in Framingham, Massachusetts, a Boston suburb. The study was soon incorporated into the newly established National Heart Institute (NHI), part of the National Institutes of Health (NIH), by NHI director C. J. Van Slyke. Felix Moore, the chief of biometrics at NHI, was charged with estimating the required sample size for a definitive epidemiological study that had a reasonable likelihood of establishing, during a twenty-year period, the relationship between given characteristics and the risk of death from heart attack. This resulted in a study sample of 5,209 Framingham men and women between the ages of thirty and sixty.

Early opposition to epidemiological studies at NIH was overcome, in part due to the arguments of Van Slyke's chief cardiological advisor, Boston cardiologist Paul Dudley White, who had become interested in the natural history of heart diseases as a student in England. Dr. Thomas Dawber was appointed director of the study, and he brought his own ideas to what was to become the best-known cohort study of all time. In his book, The Framingham Study (1980), Dawber wrote:

The task of epidemiology … is to determine to what degree an observed relationship may be the result of chance and at what point the relationship is sufficiently strong that it may well be involved in causality (p. 5).

The characteristics of persons who already have the disease are not necessarily the same as those that predispose to the disease. Observations of population characteristics must be made well before disease becomes overt if the relationship of these characteristics to the development of the disease is to be established with reasonable certainty (p.11).

If the relationship is one that fits what is known about the disease and has a logical explanation, it is worth exploring further, regardless of the strength of the relationship. If, however, the relationship is very powerful, it deserves careful scrutiny even though the alleged relationship may be unexplained at the time (p. 4).

The ongoing Framingham Study has remained the responsibility of the NHI, which was renamed the National Heart, Lung, and Blood Institute (NHLBI) in 1976, and it is carried out under contract by researchers at the Boston University School of Medicine. It has been enlarged twice, in 1971 with the "Offspring Study," which added 5,124 children (and their spouses), to the original study participants, and in the late 1990s with the "Omni Study" of minorities. Every other year, after an extensive baseline examination, subjects undergo testing that includes a medical history, blood profile, echocardiogram, and bone, eye, and other specialized tests.

The Framingham Study produced a landmark report on the predictive power of blood pressure, blood cholesterol level, and cigarette smoking for heart and blood vessel diseases (Dowbar et al.,1957). The term "risk factor" is, in fact, attributed to the investigators of Framingham, who have also gone on to elaborate many central concepts and practical tools in the identification and prevention of elevated cardiovascular risk. Among their discoveries are:

  • Knowledge about the relationship between blood vessel diseases and blood cholesterol fractions, LDL ("bad") cholesterol and HDL ("good") cholesterol.
  • "Multivariate risk"—the more-than-additive contribution to risk of multiple factors present together.
  • The greater predictive precision of systolic, rather than diastolic, blood pressure levels.
  • Discounting the "common wisdom" that high blood pressure is less dangerous in women and the elderly.
  • The rising risk of cardiovascular diseases among women after menopause.
  • The halving of heart attack risk within a few years after stopping smoking.

The Framingham Study, with congruent findings from other studies in the United States and abroad, sparked a revolution in understanding the individual and the mass causes, as well as the preventability, of heart attack and stroke. It provided a sound basis for successful medical action and health-promotion policies to reduce the death rate from these diseases.

Under the leadership of William Kannel, in recent years the Framingham researchers have also studied the risk of particular disease manifestations such as heart failure, peripheral artery disease, stroke types, and arrhythmias. New risk characteristics such as the apolipoproteins and their regulating genes, homocysteine, blood clotting factors, and inflammation have also been examined. The scope of the study has widened to include chronic conditions such as obesity, diabetes, cardiac enlargement, osteoporosis, cancer, and Alzheimer's disease.

(SEE ALSO: Behavior, Health-Related; Cardiovascular Diseases; Chronic Illness; Cohort Study; Coronary Artery Disease; Epidemiologic Transition; Multifactorial Diseases; National Institutes of Health; Noncommunicable Disease Control; Observational Studies; Risk Assessment, Risk Management)

Bibliography

Dawber, T. R. (1980). The Framingham Study. The Epidemiology of Atherosclerotic Disease. Cambridge, MA: Harvard University Press.

Dawber, T. R.; Moore, F. E., Jr.; and Mann, G. V. (1957). "Coronary Heart Disease in the Framingham Study." American Journal of Public Health 47:4–24.

Kannel, W. B. (1995). "Clinical Misconceptions Dispelled by Epidemiological Research. The Ancel Keys Lecture." Circulation 92:3350–3360.

— HENRY BLACKBURN



Search unanswered questions...
Enter a word or phrase...
All Community Q&A Reference topics
Wikipedia: Framingham Heart Study
 

The Framingham Heart Study is a cardiovascular study based in Framingham, Massachusetts. The study began in 1948 with 5,209 adult subjects from Framingham, and is now on its third generation of participants. Prior to it almost nothing was known about "the epidemiology of hypertensive or arteriosclerotic cardiovascular disease.[1]" Much of the now-common knowledge concerning heart disease, such as the effects of diet, exercise, and common medications such as aspirin, is based on this longitudinal study. It is a project of the National Heart, Lung, and Blood Institute, in collaboration with (since 1971) Boston University. Various health professionals from the hospitals and universities of Greater Boston staff the project.

Thomas Royle Dawber was Director of the study from 1949 to 1966. He was appointed as chief epidemiologist shortly after the start of the project, when it was not progressing well.[2] The study had been intended to last 20 years, but at that time Dawber moved to Boston and became chairman of preventive medicine, raising funds to continue the project and taking it with him.

One of the crucial questions in evidence-based medicine is how closely the people in a study resemble the patient you are dealing with.[3] Recently the Framingham studies have become regarded as overestimating risk, particularly in the lower risk groups, for UK populations.[4] There has been widespread discussion of the study, and it is generally accepted that the work is outstanding in its scope and duration, and is overall considered very useful. Researchers recently used contact information given by subjects over the last 30 years to map the social network of friends and family in the study.[5]

The initial population was 5,209 healthy men and women aged 30 to 60, not the whole of the town population, as is sometimes assumed. A similar longitudinal study has been carried out in a high proportion of the residents of Busselton, a town in Western Australia, over a period of many years;[6] however, Framingham is more widely cited.

Footnotes

  1. ^ Thomas R. Dawber, M.D., Gilcin F. Meadors, M.D., M.P.H., and Felix E. Moore, Jr., National Heart Institute, National Institues of Health, Public Health Service, Federal Security Agensy, Washington, D. C., Epidemiological Approaches to Heart Disease: The Framingham Study Presented at a Joint Session of the Epidemiology, Health Officers, Medical Care, and Statistics Sections of the American Public Health Association, at the Seventy-eighth Annual Meeting in St. Louis, Mo., November 3, 1950.
  2. ^ Richmond (2006). "Obituary: Thomas Royle Dawber" (fee required). BMJ 332: 122. doi:10.1136/bmj.332.7533.122. http://bmj.bmjjournals.com/cgi/content/full/332/7533/122. 
  3. ^ David Hadden (7 September 2002). "Holidays in Framingham?". BMJ 325: 544. doi:10.1136/bmj.325.7363.544. http://bmj.bmjjournals.com/cgi/content/full/325/7363/544. 
  4. ^ Brindle P, Emberson J, Lampe F, et al. (2003). "Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study". BMJ 327 (7426): 1267. doi:10.1136/bmj.327.7426.1267. PMID 14644971. 
  5. ^ Nicholas A. Christakis and James H. Fowler. (2007). "The Spread of Obesity in a Large Social Network Over 32 Years," New England Journal of Medicine 357 (4): 370-379
  6. ^ A list of publications from the Busselton study

Works cited

  • Daniel Levy and Susan Brink. (2005). A Change of Heart: How the People of Framingham, Massachusetts, Helped Unravel the Mysteries of Cardiovascular Disease. Knopf. ISBN 0-375-41275-1.

External links


 
 

 

Copyrights:

Encyclopedia of Public Health. Encyclopedia of Public Health. Copyright © 2002 by The Gale Group, Inc. All rights reserved.  Read more
Wikipedia. This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Framingham Heart Study" Read more